UK Markets open in 52 mins
  • NIKKEI 225

    -841.00 (-3.11%)

    -719.15 (-2.96%)

    -0.74 (-0.85%)

    -20.30 (-1.11%)
  • DOW

    -129.61 (-0.38%)

    -962.27 (-3.45%)
  • CMC Crypto 200

    -33.10 (-3.87%)
  • Nasdaq

    +2.82 (+0.02%)
  • ^FTAS

    +53.23 (+1.29%)

Global Biosimulation Market Research Report 2021-2028 - Surging Demand for Biosimulation Software & Services due to their Higher Cost-Efficiency

·3-min read

Dublin, Dec. 30, 2021 (GLOBE NEWSWIRE) -- The "Global Biosimulation Market Size, Share & Trends Analysis Report by Product (Software, Services), by Application (Drug Development, Drug Discovery), by End Use, by Region, and Segment Forecasts, 2021-2028" report has been added to's offering.

The global biosimulation market is anticipated to reach USD 6.83 billion by 2028. The market is expected to expand at a CAGR of 15.9% from 2021 to 2028. The key factors fueling the market growth include the increasing incidence of chronic diseases, increase in healthcare digitization, and usage of biosimulation solutions in clinical trials and research.

The need for drug discovery and development amidst the prevalence of acute and chronic diseases has resulted in an increase in the allocation of funds for R&D activities, which has propelled the adoption of biosimulation solutions. In addition, a high drug attrition rate leads to an increase in the cost of clinical trials, which is expected to drive the clinical urgency to incorporate in silico biology approach. This approach significantly reduces the probability of drug failure by predicting biological interactions, thereby reducing the overall costs.

Arise in drug relapse rates, drug resistance cases, and limited availability of drugs to treat diseases such as AIDS have led to high clinical urgency for the adoption of biosimulation in applications, such as drug development and drug discovery.

The COVID-19 pandemic also had a significant impact on the market. Simulations Plus, for instance, launched the StrategiesPlus COVID-19 ACT Program in March 2020 for speeding consulting assistance to any organization involved in the COVID-19 research. As of November 2020, the company declared that its business was not materially adversely affected. However, the continuing spread of COVID-19 and the measures taken by the governments of the affected countries are likely to disrupt the supply chain and adversely impact its business and financial performance.

Surging demand for biosimulation software and services can also be attributed to their higher cost-efficiency. Biosimulation solutions enable cost-effective prediction of toxicity, adverse reactions, and efficacy of investigational drugs during early stages of product development, thus limiting the probability of drug relapse and adverse events at later stages.

Market Highlights

  • In terms of product, software dominated the market in 2020. This can be attributed to the availability of a wide range of application-specific software that suits research requirements. Furthermore, biosimulation software is being used in clinical trials and it also eases modeling and target drug identification

  • By application, the drug development segment accounted for the largest share in 2020

  • Based on end use, pharmaceutical and biotechnology companies dominated the market in 2020 due to increasing strategic initiatives

  • North America grabbed the largest share in 2020. The presence of a favorable reimbursement framework (especially post the implementation of the Affordable Care Act) and sophisticated healthcare infrastructure is expected to drive the North American market over the forecast period

  • Asia Pacific is expected to grow significantly during the forecast period owing to the increase in the number of CROs, growth in spending on healthcare IT, and rapidly evolving healthcare infrastructure

Key Topics Covered

Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Biosimulation Market Variables, Trends & Scope
Chapter 4 Biosimulation Market: Impact of COVID-19
Chapter 5 Biosimulation Market: Segment Analysis, By Product, 2016-2028 (USD Million)
Chapter 6 Biosimulation Market: Segment Analysis, By Application, 2016-2028 (USD Million)
Chapter 7 Biosimulation Market: Segment Analysis, By End Use, 2016-2028 (USD Million)
Chapter 8 Biosimulation Market: Regional Market Analysis 2016-2028 (USD Million)
Chapter 9 Biosimulation Market - Competitive Analysis
Chapter 10 Biosimulation Market - Company Profiles

  • Certara

  • Simulations Plus

  • DassaultSystemes

  • Schrodinger, Inc.

  • Advanced Chemistry Development

  • Chemical Computing Group ULC

  • Physiomics plc

  • Rosa & Co. LLC.

  • BioSimulation Consulting Inc.

  • Genedata AG

  • Instem Group of Companies

  • PPD, Inc. (Evidera)

  • Insilico Biotechnology AG

  • Immunetrics

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting